INTRODUCTION {#sec1-1}
============

Anticoagulant (AC) and antiplatelet (AP) agents are widely used to manage thrombotic complications, which may be frequently observed in patients with hematological malignancies (HM).\[[@CIT1]--[@CIT4]\] However, patients with HM may be at high risk of hemorrhagic complications due to different form of coagulopathies, several degrees of thrombocytopenia, and associated comorbidities.\[[@CIT5][@CIT6]\] So that, the safe administration of these agents in this setting represents a matter of debate, also in the light of the paucity of data regarding this issue available in the medical literature. In this regard, we have performed a single-center prospective survey on a series of consecutive patients with HM in advanced phase of disease followed in a home care setting.

MATERIALS AND METHODS {#sec1-2}
=====================

A prospective evaluation of the use of anticoagulant and anti-thrombotic agents, as well as the bleeding and thrombotic complications in a consecutive cohort of patients followed at home during the first semester of 2010 was performed. Three pharmacological class of agents, such as oral AC (warfarin and acenocumarine), low molecular weight heparin (LMWH) and AP drugs were considered. The indication for treatment, along with any significant adverse effects potentially referable to these agents, was evaluated. All treatments were given at home, where patients were followed by a specialized and multidisciplinary trained staff, composing seven hematologists, ten nurses, and several other care providers trained in hematology, palliative care and rehabilitation medicine.\[[@CIT7]--[@CIT10]\] The availability at home of a reliable and trained caregiver was considered an essential condition to provide a home care program.\[[@CIT9]\] The home care team worked together with general services and diagnostic structures of our hospital; in the case of bleeding, all hemostatic measures, including platelet concentrates and fresh frozen plasma (FFP) transfusions, were supplied at home.\[[@CIT6]\]

RESULTS {#sec1-3}
=======

Demographic data and hematological diagnoses of patients included in the study are reported in [Table 1](#T0001){ref-type="table"}. Out of 129 patients, 26 (20%) were treated with AC/AP drugs. Acenocumarine, warfarin, LMWH and AP were used in 7, 11 and 12 patients, respectively. Treatment indication, platelets count, coexisting renal or liver dysfunctions and drug dosage adjustment are reported on [Table 2](#T0002){ref-type="table"}. Adverse events (bleeding) were observed in 3 (11.5%) out of 26 treated patients, being 2 of them on oral AC and 1 on AP; none of these 3 patients had thrombocytopenia.

###### 

Demographic data and hematological diagnoses of patients followed during observation period

  Category                                   *n*
  ---------------- ------------------------- -----
  Patients                                   129
  Age (years)      78 (20-98)                
  Gender           Male                      57
                   Female                    72
  Diagnoses        MDS/cMPD                  53
                   Acute leukemia            11
                   Lymphoma                  18
                   Plasma cell dyscrasia     12
                   Cancer-unrelated anemia   21
                   Other                     14
  Disease status   Advanced / terminal       32
                   Indolent / chronic        78
                   Active treatment          19

###### 

Treatment indication, platelets count, coexisting renal or liver failure, drug dosage modification in AC / AP patients

  Category                                                                       *n*
  -------------------- --------------------------------------------------------- -----
  Patients                                                                       26
  AC / AP indication   Primary prophylaxis [a](#T000F1){ref-type="table-fn"}     11
                       Secondary prophylaxis [b](#T000F2){ref-type="table-fn"}   14
                       Treatment                                                 1
  AC / AP target       Ischemic heart disease                                    9
                       Other heart disease                                       6
                       DVT                                                       6
                       Ischemic cerebrovascular disease                          5
  Platelets count      Low (\<150,000)                                           8
                       Normal                                                    14
                       High (\>450,000)                                          4
  Renal failure        Yes                                                       11
                       No                                                        15
  Liver failure        Yes                                                       0
                       No                                                        26
  Drug adjustment      Yes for bleeding risk                                     2
                       Yes for severe renal failure                              1
                       No                                                        23

AC - anticoagulants; AP - anti-platelet

Treatment intended to prevent the first occurrence of thrombotic event

preventive treatment for a subsequent occurrence (relapse) of thrombotic event. DVT: deep vein thrombosis

CONCLUSIONS {#sec1-4}
===========

In the management of patients with HM, thrombotic complications may represent a considerable concern, especially when they are in advanced phase of their disease and are followed at home. The incidence of these potentially devastating complications in patients with HM has been reported to be higher than that observed in the setting of solid tumors. Contributing factors include a HM-related thrombophilic state, some underlying disease activities and certain antineoplastic therapies, such as high dose corticosteroids, new immunomodulatory agents and hematopoietic growth factors. Primary and secondary pharmacological prophylaxis can be problematic in these patients, who are often concerned by thrombocytopenia, coagulopathies or co-existing diseases and organ dysfunctions for which a dosage adjustment of AC and AP drugs and a careful clinical monitoring are required. Our experience is referred to the activity of a home care services implemented in Rome,\[[@CIT7]--[@CIT10]\] during the last two decades with the aim to offer highly developed expertise to several categories of patients with HM. In our experience, the home care represented an important added value in the global management of patients with deteriorated clinical conditions, social difficulties and physical impairments, achieving an integrated model of assistance and a cost-effective form of patient's care.\[[@CIT7]\] Despite the frequent findings of hemostatic disorders in this population of frail patients managed in a home care setting, our experience demonstrated that AC and AP drugs have been very rarely responsible for significant complications.
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